Ice crystal regulator and its preparation method and application

By using an ice crystal regulator composed of fructose, magnesium chloride, inulin, sorbitol, hyaluronic acid, sodium alginate, and anthocyanins, combined with a specific freeze-drying procedure, the problem of ice crystal damage to porcine pseudorabies virus during freeze-drying at -20℃ was solved, thereby improving the viral potency and shelf life of the vaccine.

CN116135231BActive Publication Date: 2024-11-15JIANGSU ACAD OF AGRI SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111365335.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-11-17
Publication Date
2024-11-15
Estimated Expiration
2041-11-17

AI Technical Summary

Technical Problem

Porcine pseudorabies virus is susceptible to ice crystal damage at -20°C, resulting in severe loss of viral titer during freeze-drying. Existing ice crystal control technologies in the production of porcine pseudorabies live vaccines are limited to food preservation and embryo cryopreservation, and are difficult to apply to efficient freeze-drying preparation.

Method used

An ice crystal regulator composed of fructose, magnesium chloride, inulin, sorbitol, hyaluronic acid, sodium alginate, anthocyanins, and L-serine is used. By adjusting the pH value to 7.0–7.5, the mixture is mixed with the virus solution in a specific ratio and combined with a specific freeze-drying procedure to control the morphology of ice crystals and inhibit recrystallization, thereby protecting the virus structure.

Benefits of technology

It effectively reduces virus loss during storage at -20℃, improves the virus's resistance to freezing during freeze-drying, enhances vaccine product quality, controls virus titer loss to within 0.6 titers, and extends shelf life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116135231B_ABST
    Figure CN116135231B_ABST
Patent Text Reader

Abstract

The invention discloses an ice crystal regulator, a preparation method and an application thereof, wherein the ice crystal regulator comprises the following components by mass percentage: 3% to 8% fructose, 0.5% to 3% magnesium chloride, 0.5% to 5% inulin, 1% to 5% sorbitol, 1% to 5% hyaluronic acid, 0.1% to 5% sodium alginate, 0.01% to 1% anthocyanin, 0.5% to 3% L-serine, and double pure water supplemented to 100%. The ice crystal regulator of the invention is mixed with a pseudorabies virus solution in a proportion to form a vaccine semi-finished product, which is stored at -20°C for 2 months, can effectively protect pseudorabies virus from porcine, and the potency loss does not exceed 0.6Lg. After the pseudorabies live vaccine semi-finished product is frozen and thawed, it is mixed with the ice crystal regulator, and vacuum freeze-dried using a corresponding freeze-drying procedure to obtain a pseudorabies freeze-dried live vaccine, which can effectively reduce the loss of the vaccine during the freeze-drying process, and the virus activity decreases by no more than 0.8 titers, greatly improving the product quality of the pseudorabies live vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and vaccine freeze-drying manufacturing, and specifically relates to an ice crystal regulator and a preparation method and application thereof. Background Art

[0002] Ice crystals are a common natural phenomenon. Their formation involves two steps: nucleation and crystal growth. Temperature fluctuations lead to recrystallization. Ice crystals have a variety of morphologies, including more than ten types such as needle-shaped, dendritic, flat, and columnar. Their morphology is affected by solution composition, temperature, and pressure. Both ice crystals and recrystallization cause irreversible mechanical damage to biological structures and functional degradation or even loss. For example, when sperm is frozen for storage, if the water in the sperm cells freezes and forms a sharp morphology, it is easy to pierce the cell wall, causing sperm inactivation. In recent years, ice crystal regulation technology has developed rapidly. Studies have shown that small molecules such as trehalose, proline, and glycerol can control ice crystal growth by lowering the freezing point; while antifreeze proteins, graphene oxide, and microcrystalline cellulose inhibit ice crystal growth by adsorbing on the surface of ice crystals, thereby regulating ice crystal size, morphology, and inhibiting recrystallization. However, they are currently limited to areas such as food preservation and embryo cryopreservation.

[0003] Pseudorabies is an acute, febrile infectious disease caused by pseudorabies virus (PRV) infection that affects a variety of domestic animals and wild animals, causing huge economic losses to the pig industry. PRV belongs to the Herpesviridae family and the genus Porcine Herpesvirus. The virus particles are round, with a diameter of 150-180nm and a nucleocapsid diameter of 105-110nm; the outermost layer of the virus particles is a lipid capsule structure. In recent years, pseudorabies in pigs has caused serious damage to my country's pig industry. Vaccination is one of the main measures to prevent, control and eliminate pseudorabies in pigs. The immunization rate of PRV vaccine in medium and large-scale farms exceeds 50%. Live vaccines are the mainstream vaccines for the prevention of the disease, such as Bartha-K61 strain. However, there is a major problem in the production of this type of live vaccine: PRV is particularly sensitive to ice crystal damage. After freezing and freeze-drying, the virus replication ability of PRV decreases by up to 98%, greatly affecting the quality of the vaccine. The study found that after PRV was frozen and thawed at -70℃ for 2 months, the virus activity was almost not lost, but after being frozen and thawed at -20℃ for 2 months, the virus activity decreased by 1-1.5Lg. Considering that fine ice crystals are formed by freezing at -70℃ and larger ice crystals are formed by freezing at -20℃, combined with the fact that PRV virus particles are larger, it is speculated that the main factor causing damage to the virus fiber structure or even shedding during ice crystal formation and recrystallization is

[0004] Existing commercial live pseudorabies vaccines are all prepared using a freeze-drying process. The vacuum freezing process easily forms ice crystals, causing loss of viral titer. The drying process can cause damage and death to microbial cells and passivation of protein molecules. Therefore, controlling the freeze-drying preparation process of live pseudorabies vaccines from the perspective of ice crystal regulation is of great significance for the production of high-quality vaccines. Summary of the invention

[0005] Purpose of the invention: The technical problem to be solved by the present invention is that the antigen prepared from porcine pseudorabies virus is not resistant to ice crystals at -20°C, the porcine pseudorabies virus live vaccine is not resistant to ice crystal damage during the production and manufacturing process, and the freeze-drying loss product quality does not meet the requirements. An ice crystal regulator is provided, which can effectively regulate the effective preservation of the antigen at -20°C and the ice crystal morphology to be more blunt and rounded when the virus is freeze-dried, reduce the damage of ice crystals to porcine pseudorabies virus during freezing and freeze-drying, and effectively improve the quality of porcine pseudorabies live vaccine.

[0006] In order to solve the above technical problems, the present invention provides an ice crystal regulator, which includes the following components in mass percentage: 3% to 8% fructose, 0.5% to 3% magnesium chloride, 0.5% to 5% inulin, 1% to 5% sorbitol, 1% to 5% hyaluronic acid, 0.1% to 5% sodium alginate, 0.01% to 1% anthocyanin, 0.5% to 3% L-serine, and double pure water supplemented to 100%.

[0007] The present invention also includes a method for preparing the ice crystal regulator, comprising the following steps:

[0008] 1) Weigh fructose, magnesium chloride, inulin and sorbitol and dissolve them in water for injection. Dissolve them fully and heat sterilize for 15-20 minutes before use.

[0009] 2) Weigh hyaluronic acid, sodium alginate, anthocyanin, and L-serine, dissolve them in water for injection, fully dissolve, filter and sterilize, and set aside;

[0010] 3) The solutions obtained in steps 1) and 2) are mixed under sterile conditions, and the pH of the solution is adjusted to 7.0-7.5 by using an alkaline agent to obtain an ice crystal regulator.

[0011] The alkaline reagent includes but is not limited to KOH, NaOH and other alkaline reagents.

[0012] The present invention also includes the use of the ice crystal regulator in the preparation of freeze-dried vaccines.

[0013] Wherein, the volume ratio of the ice crystal regulator to the antigen is 1:15 to 1:7.

[0014] Wherein, the antigen is a herpes virus, including but not limited to porcine pseudorabies virus, and other herpes viruses are also applicable to the present invention. The herpes virus is porcine pseudorabies virus.

[0015] The culture process of the porcine pseudorabies virus includes ST cell adherent culture or ST cell full suspension culture.

[0016] The application is to mix the ice crystal regulator and the herpes virus in a volume ratio of 1:15 to 1:7 to obtain a semi-finished herpes virus live vaccine.

[0017] Among them, after the herpes virus live vaccine semi-finished product is frozen and thawed, it is evenly mixed with the ice crystal regulator at a volume ratio of 1:1 to 2:1 to obtain a vaccine solution, and vacuum freeze-dried using a corresponding freeze-drying procedure to obtain a herpes virus freeze-dried live vaccine.

[0018] The freeze-drying procedure includes the following steps: placing the vaccine solution in a freeze-drying machine body and pre-cooling it at 2 to 8°C for 15 to 45 minutes, and maintaining the temperature for 30 to 60 minutes; reducing the temperature to -35 to -40°C at a rate of 1°C / min to 3°C / min and maintaining it for 1 to 2 hours, heating it to -25 to -28°C at a rate of 0.2°C / min to 0.5°C / min and maintaining it for 2 to 4 hours, and then reducing the temperature to -35 to -40°C at a rate of 1°C / min to 2.5°C / min and maintaining it for 2 to 4 hours to freeze the vaccine; opening the cold well and reducing it to below -50 to -60°C, and evacuating it to 200mTo After lyophilization, heat it to -15~-10℃ at a rate of 0.8℃ / min~1.5℃ / min, and maintain it at this temperature for 10~12h; heat it to 4℃ at a rate of 0.3℃ / min~0.8℃ / min, and maintain it for 5~8h; heat it to 20~25℃ at a rate of 0.5℃ / min~0.8℃ / min, and maintain it for 3~5h; heat it to 28~30℃ at a rate of 1℃ / min~2℃ / min, and maintain it for 2~3h; the vacuum degree of the whole drying process is controlled at 120~200mTorr. After the freeze-drying is completed, the plug is pressed out of the box. The whole freeze-drying process is 25~34h.

[0019] The present invention also includes a freeze-dried live vaccine of pseudorabies virus, which includes the ice crystal regulator.

[0020] Wherein, the volume ratio of the porcine pseudorabies virus to the ice crystal regulator is 1:1 to 2:1.

[0021] Reaction mechanism: The fructose in the ice crystal regulator is a monosaccharide, which has the best performance in controlling the formation of ice crystals and effectively prevents the formation of ice crystals during the freeze-drying process of the virus; inulin is a natural sugar, which is rich in resources and has good biological activity. It is a fructan formed by connecting D-furanose molecules through β-(2,1)-glycosidic bonds, with a straight chain structure, and the end is connected to a molecule of glucose residue as an inhibitor through α-(1,2)-glycosidic bonds. It forms a glassy state during the freeze-drying process and has the effect of inhibiting the formation of ice crystals. Anthocyanin is a natural polyphenol antioxidant, which can effectively protect the virus structure when combined with L-serine during virus freeze-drying. The composite ice crystal regulator of the present invention is freeze-dried in accordance with a suitable ratio during the freeze-drying process, which can inhibit the aggregation of proteins, reduce surface adsorption, and play a role in skeleton support, and cooperate with each other to achieve the best effect of protecting the virus titer. The PRV virus is round or oval, and its structure is easily damaged during the freeze-drying process, which affects the virus titer and the quality of the later products. Adding the above-mentioned ice crystal regulator and the matching freeze-drying program for freeze-drying can effectively reduce the freezing point, modify the ice crystal morphology, inhibit recrystallization, improve the virus's antifreeze ability, and effectively improve the quality of the vaccine product. After adding the ice crystal regulator in the present invention, the ice crystal size can be effectively adjusted to 50% of the original size by observation under a scanning electron microscope, and the virus structure is more complete than before. During the experiment, when the porcine pseudorabies virus without the addition of the ice crystal regulator was stored at -20°C for 7 days, or when the components of the ice crystal regulator of the present invention lacked hyaluronic acid or anthocyanin, the virus loss was far greater than 1.0Lg; the vaccine lost 1.0-1.5Lg in potency during the freeze-drying process. By using the ice crystal regulator for the low-toxic live pseudorabies vaccine of the present invention, the pseudorabies virus of the porcine can be stored at -20°C for 2 months, and the virus content loss is only within 0.6Lg, which effectively prolongs the shelf life of the semi-finished product of the vaccine product and solves the problem that the virus is not resistant to freezing at -20°C; at the same time, the ice crystal regulation technology and the matching freeze-drying procedure are freeze-dried with the virus, which greatly improves the quality of the vaccine product.

[0022] Beneficial effects: Compared with the prior art, the present invention has the following advantages:

[0023] (1) The ice crystal regulator of the present invention effectively protects the semi-finished live vaccine of pseudorabies in pigs, can effectively solve the problem that the pseudorabies virus in pigs is not easy to store at -20°C, and can also effectively protect the live vaccine of pseudorabies in pigs from the problem that the virus is not resistant to freezing during freeze drying. The semi-finished vaccine product in which the ice crystal regulator is evenly mixed with the pseudorabies virus solution in proportion can be stored at -20°C for 2 months, and the pseudorabies virus in pigs can be effectively protected, with a potency loss of no more than 0.6Lg.

[0024] (2) The ice crystal regulator and the regulation method are applicable to different cell proliferation processes of porcine pseudorabies virus, including but not limited to ST cell adherent culture or ST cell full suspension culture porcine pseudorabies virus proliferation process.

[0025] (3) The ice crystal regulator and the regulation method are applied to the freeze-dried preparation of the live pseudorabies vaccine of porcine. After the semi-finished live pseudorabies vaccine of porcine is frozen and thawed, it is evenly mixed with the ice crystal regulator at a volume ratio of 1:1 to 2:1, and then vacuum freeze-dried using the corresponding freeze-drying procedure to obtain the freeze-dried live pseudorabies vaccine of porcine. The loss of the vaccine during the freeze-drying process is effectively reduced, and the viral activity decreases by no more than 0.8 titers, thereby greatly improving the product quality of the live pseudorabies vaccine of porcine. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is a scanning electron micrograph of the PRV after adherent culture in Example 4;

[0027] Figure 2 This is a scanning electron micrograph of the PRV cultured after the ice crystal regulator was added in Example 4;

[0028] Figure 3 This is a scanning electron micrograph of the PRV after suspension culture in Example 4;

[0029] Figure 4 This is a scanning electron micrograph of the PRV cultured with the addition of an ice crystal regulator in Example 4. DETAILED DESCRIPTION

[0030] The present invention will be further described below in conjunction with the accompanying drawings and embodiments.

[0031] Porcine pseudorabies virus, ST adherent cells, and ST suspension cells were provided by the Institute of Animal Immunology Engineering, Jiangsu Academy of Agricultural Sciences.

[0032] ST adherent culture process of pseudorabies virus liquid in pigs: Take the pseudorabies virus sample of pigs, dilute it 100 times with 2% DMEM, and inoculate the ST adherent cultured cells. After culturing at 37℃ for 42-46h, harvest the virus liquid, freeze and thaw it three times, filter it with gauze, harvest the supernatant, keep the sample and freeze it at -20℃. It was sterile after inspection, and the virus content was determined to be 10 8.0 TCID 50 / ml or above can be used in the preparation of pseudorabies semi-finished products and vaccine products.

[0033] ST suspension culture process of pseudorabies virus liquid: Take the pseudorabies virus sample of pigs, dilute it 100 times with 2% DMEM, and inoculate the ST suspension cultured cells. After culturing at 37℃ for 42-46h, harvest the virus liquid, freeze and thaw it three times, filter it with gauze, harvest the supernatant, keep the sample and freeze it at -20℃. It was sterile after inspection, and the virus content was determined to be 108.0 TCID 50 / ml or above can be used in the preparation of pseudorabies semi-finished products and vaccine products.

[0034] The present invention mixes the prepared ice crystal regulator with the prepared porcine pseudorabies virus live vaccine semi-finished product at a ratio of 1:7-1:15, packages the mixture, stores the mixture at -20°C for a certain period of time for freeze drying, and determines the virus titer of the semi-finished product.

[0035] Main technical parameters and detection methods of semi-finished porcine pseudorabies live vaccine: virus content detection method.

[0036] The virus content was determined according to the method and standard in the appendix of the Veterinary Pharmacopoeia of the People's Republic of China. The semi-finished product of pseudorabies vaccine was diluted 10 times with 2% DMEM, and 10 -5 -10 -8 , 4 dilutions, each dilution was inoculated into 6 passage cell (ST) monolayer wells, and the positive control and negative control were also inoculated into 6 wells, 0.1 ml per well, and cultured at 37℃+1℃, 5% CO2 for 72h to check the virus-specific cytopathic effect and calculate TCID according to the Reed-Muench method 50 The virus content of each vaccine dose should not be less than 10 5.5 TCID 50 / ml.

[0037] The ice crystal regulator of the present invention is used in the preparation of a finished product of a live pseudorabies virus vaccine of swine: after the semi-finished live pseudorabies vaccine is frozen and thawed, it is evenly mixed with the ice crystal regulator at a volume ratio of 1:1 to 2:1, and then packaged into 2 ml / bottles, sealed with rubber stoppers, and quickly placed in a pre-cooled freeze-drying machine cabinet, and freeze-vacuum dried according to the freeze-drying curve provided by the present invention.

[0038] Main technical parameters and test methods of finished porcine pseudorabies virus live vaccine products: The physical properties and residual moisture content of porcine pseudorabies virus live vaccine products are determined in accordance with the methods and standards in the appendix of the current "Pharmacopoeia of the People's Republic of China".

[0039] Virus content detection method of live pseudorabies virus vaccine products: Virus content determination According to the detoxification content indicated on the bottle label, the vaccine is re-dissolved in 2% DMEM and then diluted 10 times. -5 -10 -8 , 4 dilutions, each dilution was inoculated into 6 passage cell (ST) monolayer wells, and the positive control and negative control were also inoculated into 6 wells, 0.1 ml per well, and cultured at 37℃+1℃ / 5% CO2 for 72h, and the virus-specific cytopathic effect was examined and TCID was calculated according to the Reed-Muench method 50 When leaving the factory, the virus content of each vaccine should not be less than 105.5 TCID 50 / ml.

[0040] The control products were stored at 4°C and 37°C, and samples were taken at different times to determine the virus content.

[0041] Example 1 Preparation of Ice Crystal Regulator 1 and Pseudorabies Virus Semi-finished Product

[0042] Preparation of ice crystal regulator 1:

[0043] Step 1, by mass percentage: weigh 3% fructose, 0.5% magnesium chloride, 0.5% inulin, and 1% sorbitol, dissolve in water for injection, fully dissolve and heat sterilize at 115°C for 15-20 minutes;

[0044] Step 2: Weigh 1% hyaluronic acid, 0.1% sodium alginate, 0.01% anthocyanin, and 0.5% L-serine and dissolve them in water for injection until fully dissolved. Filter through a 0.22 μm filter for sterilization.

[0045] The solutions prepared in step 1 and step 2 are mixed under sterile conditions, and the pH of the solution is adjusted to 7.0-7.5 by KOH to obtain ice crystal regulator 1.

[0046] Preparation of semi-finished live pseudorabies vaccine: ice crystal regulator 1 was mixed with pseudorabies virus solution obtained by ST adherent culture or pseudorabies virus solution obtained by ST suspension culture at a volume ratio of 1:8 to obtain semi-finished live pseudorabies vaccine, which was frozen at -20°C and the virus titer at different times was measured (see Table 1)

[0047] Table 1 shows the virus titer and loss during the shelf life of the semi-finished product of pseudorabies virus ice crystal regulator 1

[0048]

[0049] It can be seen from the test data in Table 1 that ice crystal regulator 1 was added to the semi-finished product of porcine pseudorabies live vaccine during storage. The porcine pseudorabies virus antigens cultured by the two processes were stored at -20°C for 60 days, and the virus losses were 0.57 and 0.60 titers respectively, indicating that the ice crystal regulator can effectively protect the virus titer.

[0050] Example 2 Preparation of Pseudorabies Virus Ice Crystal Regulator 2 and Semi-finished Product

[0051] Preparation of ice crystal regulator 2:

[0052] Step 1: Dissolve 5% fructose, 1.5% magnesium chloride, 2.5% inulin and 3% sorbitol in water for injection, fully dissolve and sterilize by heating at 115°C for 15-20 minutes;

[0053] Step 2: Weigh 3% hyaluronic acid, 2.5% sodium alginate, 0.05% anthocyanin, and 1.5% L-serine and dissolve them in water for injection until fully dissolved. Filter through a 0.22 μm filter for sterilization.

[0054] The solutions obtained in step 1 and step 2 are mixed under sterile conditions, and the pH of the solution is adjusted to 7.0-7.5 by a regulating solution to obtain an ice crystal regulating agent 2.

[0055] Ice crystal regulator 2 was mixed with the porcine pseudorabies virus solution obtained by ST adherent culture or the porcine pseudorabies virus solution obtained by ST suspension culture at a volume ratio of 1:10 to obtain the semi-finished porcine pseudorabies live vaccine, which was frozen at -20°C and the virus titer was measured at different times (see Table 2).

[0056] Table 2 shows the virus titer and loss during the shelf life of the semi-finished product of pseudorabies virus ice crystal regulator 2

[0057]

[0058] It can be seen from the test data in Table 2 that ice crystal regulator 2 was added during the storage of the semi-finished product of pseudorabies virus. The pseudorabies virus antigens cultured by the two processes were stored at -20°C for 60 days, and the virus losses were 0.55 and 0.58 titers respectively, which effectively protected the virus titer.

[0059] Example 3 Preparation of Pseudorabies Virus Ice Crystal Regulator 3 and Semi-finished Product

[0060] Preparation of ice crystal regulator 3:

[0061] Step 1: Dissolve 8% fructose, 3% magnesium chloride, 5% inulin and 5% sorbitol in water for injection, fully dissolve and sterilize by heating at 115°C for 15-20 minutes;

[0062] Step 2: Dissolve 5% hyaluronic acid, 5% sodium alginate, 1% anthocyanin and 3% L-serine in water for injection until fully dissolved, and filter through a 0.22 μm filter for sterilization.

[0063] The solutions obtained in step 1 and step 2 are mixed under sterile conditions, and the pH of the solution is adjusted to 7.0-7.5 by a regulating solution to obtain an ice crystal regulating agent 3.

[0064] Ice crystal regulator 3 was mixed with the porcine pseudorabies virus solution obtained by ST adherent culture or the porcine pseudorabies virus solution obtained by ST suspension culture at a volume ratio of 1:15 to obtain a semi-finished porcine pseudorabies live vaccine, which was frozen at -20°C and the virus titer was measured at different times (see Table 3).

[0065] Table 3 shows the virus titer and loss during the shelf life of the semi-finished product of pseudorabies virus ice crystal regulator 3

[0066]

[0067] It can be seen from the test data in Table 3 that ice crystal regulator 3 was added when the pseudorabies virus semi-finished product was stored. The pseudorabies virus antigens cultured by the two processes were stored at -20°C for 60 days, and the virus losses were 0.52 and 0.60 titers respectively, both of which effectively protected the virus titer.

[0068] Therefore, it can be seen from the test data in Tables 1 to 6 that adding ice crystal regulators when storing semi-finished products of porcine pseudorabies virus can effectively inhibit the recrystallization of ice crystals, regulate the morphology of ice crystals, reduce the growth rate of ice crystals, reduce the damage caused by ice crystals to the virus during freezing, and enhance its resistance to ice damage. It effectively solves the problem that pseudorabies virus is difficult to preserve at -20°C, and the storage period can reach 60 days, and the virus loss can be controlled at 0.6 titers or below.

[0069] Example 4 Application of ice crystal regulator 1 in freeze-dried preparation of live pseudorabies vaccine

[0070] After the semi-finished product of the live pseudorabies vaccine prepared in Example 1 was frozen and thawed, it was evenly mixed with the ice crystal regulator 1 at a volume ratio of 1:1, and packaged into 2 ml / bottle, sealed with a rubber stopper, and quickly placed in a pre-cooled freeze-drying machine cabinet, and freeze-dried using the following freeze-drying procedure. The vaccine solution was placed in the freeze-drying machine cabinet and pre-cooled at 4°C for 15 minutes, and the temperature was maintained for 30 minutes. The temperature was lowered to -35 at a rate of 1°C and maintained for 1h, then raised to -25°C at a rate of 0.2°C / min and maintained for 2h, and then lowered to -35°C at a rate of 1°C / min and maintained for 2h to freeze the vaccine; after opening the cold well and dropping to below -50°C and vacuuming to 200mTorr, the temperature was raised to -15 at a rate of 0.8°C / min and maintained at this temperature for 10h; then raised to 4°C at a rate of 0.3°C / min and maintained for 5h; then raised to 20°C at a rate of 0.5°C / min and maintained for 3h; then raised to 28°C at a rate of 1°C / min and maintained for 2h. The vacuum degree of the entire drying process was controlled at 120mTorr. After the freeze-drying was completed, the plug was pressed out of the box. The entire freeze-drying process was 25h. At the same time, the live pseudorabies virus without the addition of ice crystal regulator was used as a control, and the results are shown in Table 4.

[0071] Table 4 shows the application of ice crystal regulator 1 in freeze-dried preparation of live pseudorabies vaccine

[0072]

[0073] It can be seen from the test data in Table 4 that the porcine pseudorabies virus cultured by the two processes did not use ice crystal regulator 1, and the virus loss after freeze-drying was 1.06 titers; after mixing with ice crystal regulator 1 and freeze-drying, the virus freeze-drying losses were 0.40 and 0.49 titers respectively; the heat resistance losses of the virus at 37℃ for 10d were 0.20 and 0.18 titers respectively, and the comprehensive loss was between 0.60 and 0.67 titers, which effectively protected the virus titer and improved the quality of the vaccine product.

[0074] Example 5 Application of ice crystal regulator 2 in freeze-drying preparation of live pseudorabies vaccine

[0075] The semi-finished porcine pseudorabies live vaccine prepared in Example 2 was frozen and thawed, and then uniformly mixed with ice crystal regulator 2 at a volume ratio of 1.5:1, and packaged into 2 ml / bottle, sealed with a rubber stopper, and quickly placed in a pre-cooled freeze-drying machine cabinet. The vaccine solution was placed in the freeze-drying machine cabinet and pre-cooled at 4°C for 20 minutes, and the temperature was maintained for 45 minutes. The temperature was lowered to -38℃ at a rate of 2.5℃ / min and maintained for 1.5h, then raised to -26℃ at a rate of 0.35℃ / min and maintained for 3h, and then lowered to -38℃ at a rate of 1.5℃ / min and maintained for 3h to freeze the vaccine; after opening the cold well and dropping to below -55℃ and vacuuming to 200mTorr, the temperature was raised to -12℃ at a rate of 1.0℃ / min and maintained at this temperature for 11h; then raised to 4℃ at a rate of 0.5℃ / min and maintained for 6h; then raised to 22℃ at a rate of 0.65℃ / min and maintained for 4h; then raised to 29℃ at a rate of 1.5℃ / min and maintained for 2.5h. The vacuum degree of the entire drying process was controlled at 150mTorr. After the freeze-drying was completed, the plug was pressed out of the box. The entire freeze-drying process was 25 to 34h. At the same time, the live pseudorabies virus without ice crystal regulator was used as a control. The test results are shown in Table 5.

[0076] Table 5 shows the application loss of ice crystal regulator 2 in freeze-dried preparation of live pseudorabies vaccine

[0077]

[0078]

[0079] It can be seen from the test data in Table 5 that the porcine pseudorabies virus cultured by the two processes did not use ice crystal regulator 2, and the virus loss after freeze-drying was 1.28 titers; after mixing with ice crystal regulator 2 and freeze-drying, the virus freeze-drying losses were 0.42 and 0.50 titers, respectively, which were effectively controlled at 0.5 virus titers; the heat resistance losses of the virus at 37°C for 10 days were 0.15 and 0.20 titers, respectively, and the comprehensive loss was 0.57-0.70 titers, which effectively protected the virus titer and improved the quality of the vaccine product.

[0080] Example 6 Application of ice crystal regulator 3 in freeze-drying preparation of live pseudorabies vaccine

[0081] The semi-finished live pseudorabies vaccine prepared in Example 3 was uniformly mixed with ice crystal regulator 3 at a volume ratio of 2:1, and packaged into 2 ml / bottle, sealed with a rubber stopper, and quickly placed in a pre-cooled freeze-drying machine for freeze-drying. The vaccine solution was placed in the freeze-drying machine for pre-cooling at 4°C for 45 minutes, and the temperature was maintained for 60 minutes. The temperature was lowered to -40℃ at a rate of 3℃ / min and maintained for 2h, then raised to -28℃ at a rate of 0.5℃ / min and maintained for 4h, and then lowered to -40℃ at a rate of 2.5℃ / min and maintained for 4h to freeze the vaccine; after opening the cold well and dropping to below -60℃ and vacuuming to 200mTorr, the temperature was raised to -10℃ at a rate of 1.5℃ / min and maintained at this temperature for 12h; then raised to 4℃ at a rate of 0.8℃ / min and maintained for 5-8h; then raised to 25℃ at a rate of 0.8℃ / min and maintained for 5h; then raised to 30℃ at a rate of 2℃ / min and maintained for 3h. The vacuum degree of the entire drying process was controlled at 200mTorr. After the freeze-drying was completed, the plug was pressed out of the box. The entire freeze-drying process was 25-34h. At the same time, the live pseudorabies virus without ice crystal regulator was used as a control. The test results are shown in Table 6.

[0082] Table 6 shows the application loss of ice crystal regulator 3 in freeze-dried preparation of live pseudorabies vaccine

[0083]

[0084]

[0085] It can be seen from the test data in Table 6 that the porcine pseudorabies virus cultured by the two processes did not use ice crystal regulator 3, and the virus lost more than 1.0 titer after freeze-drying; after mixing with ice crystal regulator 3 and freeze-drying, the virus freeze-drying losses were 0.38 and 0.45 titers respectively; the heat resistance losses of the virus at 37℃ for 10d were 0.15 and 0.20 titers respectively, and the comprehensive loss was 0.57-0.70 titers, which effectively protected the virus titer and improved the quality of the vaccine product.

[0086] Comparative Example 1 Ice crystal regulator control group 1

[0087] Preparation of ice crystal regulator control group 1:

[0088] Step 1: by mass percentage: 8% fructose, 5% inulin, 5% sorbitol, 3% magnesium chloride, dissolved in water for injection, fully dissolved and sterilized by heating at 115°C for 15-20 minutes;

[0089] Step 2: Dissolve 1% anthocyanin, 3% L-serine, and 5% sodium alginate in water for injection, fully dissolve, and filter with a 0.22 μm filter for sterilization. Mix the solutions obtained in step 1 and step 2 under sterile conditions, and adjust the pH of the solution to 7.0-7.5 with KOH to obtain ice crystal regulator control group 1.

[0090] The ice crystal regulator control group 1 was mixed with the pseudorabies virus solution obtained by ST adherent culture or the pseudorabies virus solution obtained by ST suspension culture at a volume ratio of 1:15 to obtain a pseudorabies live vaccine semi-finished product, which was frozen at -20°C and the virus titer was measured at different times.

[0091] The procedure of freeze-drying process control 1: freeze-thaw the prepared pseudorabies live vaccine semi-finished product, mix it evenly with ice crystal regulator control 1 at a volume ratio of 2:1, package it into 2 ml / bottle, seal it with a rubber stopper, and quickly place it in a pre-cooled freeze-drying machine box for freeze-drying. The freeze-drying process is shown in Example 6, and the results are shown in Table 7.

[0092] Table 7 shows the application loss of different ice crystal regulators in the freeze-drying preparation of live pseudorabies vaccine

[0093]

[0094]

[0095] It can be seen from the test data in Table 7 that when the pseudorabies virus cultured by the two processes was added to the ice crystal regulator control group 1, the virus loss after freeze-drying was greater than 1.0 titer, and the comprehensive loss was greater than 1.5 titer; after mixing with the ice crystal regulator 3 of Example 3 and freeze-dried, the virus freeze-drying losses were 0.38 and 0.45 titers, respectively; the heat resistance losses of the virus at 37°C for 10d were 0.15 and 0.20 titers, respectively, and the comprehensive loss was between 0.57 and 0.70 titers, which effectively protected the virus titer and improved the quality of the vaccine product.

[0096] Comparative Example 2 Ice Crystal Control Technology Control Group 2

[0097] Preparation of Ice Crystal Control Technology Control Group 2:

[0098] Step 1: by mass percentage: 8% fructose, 5% inulin, 5% sorbitol, 3% magnesium chloride, dissolved in water for injection, fully dissolved and sterilized by heating at 115°C for 15-20 minutes;

[0099] Step 2: 5% hyaluronic acid, 3% L-serine and 5% sodium alginate are dissolved in water for injection, fully dissolved and sterilized by filtration with a 0.22 μm filter. The solutions prepared in step 1 and step 2 are mixed under sterile conditions, and the pH of the solution is adjusted to 7.0-7.5 by a regulating solution to obtain an ice crystal regulating agent control group 2.

[0100] The ice crystal regulator control group 2 was mixed with the pseudorabies virus solution obtained by ST adherent culture or the pseudorabies virus solution obtained by ST suspension culture at a volume ratio of 1:15 to obtain a pseudorabies live vaccine semi-finished product, which was frozen at -20°C and the virus titer was measured at different times.

[0101] The procedure of freeze-drying process control 2: freeze-thaw the prepared pseudorabies live vaccine semi-finished product, mix it evenly with ice crystal regulator control 2 at a volume ratio of 2:1, package it into 2 ml / bottle, seal it with a rubber stopper, and quickly place it in a pre-cooled freeze-drying machine box for freeze-drying. For the freeze-drying process, see Example 6.

[0102] Table 8 shows the application loss of ice crystal regulation technology comparative example 2 in freeze-dried preparation of live pseudorabies vaccine

[0103]

[0104]

[0105] It can be seen from the test data in Table 8 that when the pseudorabies virus cultured by the two processes was added to the ice crystal regulator control group 2 of comparative example 2, the virus loss after freeze-drying was greater than 1.0 titer, and the comprehensive loss was greater than 1.5 titer; after mixing with the ice crystal regulator 3 of Example 3 and freeze-dried, the virus freeze-drying losses were 0.38 and 0.45 titers, respectively; the heat resistance losses of the virus at 37°C for 10d were 0.15 and 0.20 titers, respectively, and the comprehensive loss was between 0.57 and 0.70 titers, which effectively protected the virus titer and improved the quality of the vaccine product.

[0106] Therefore, from the comprehensive results of Example 3 and Comparative Examples 1 and 2, it can be concluded that the ice crystal regulating agent must be used in combination with anthocyanin and hyaluronic acid, and neither of them can be missing.

[0107] Comparative Example 3 Ice Crystal Control Technology Control Group 3

[0108] The semi-finished live pseudorabies vaccine prepared in Example 3 was uniformly mixed with ice crystal regulator 3 at a volume ratio of 2:1, and packaged into 2 ml / bottle, sealed with a rubber stopper, and quickly placed in a pre-cooled freeze-drying machine for freeze-drying. The vaccine solution was placed in the freeze-drying machine to pre-cool at 4°C for 30 minutes, and the temperature was maintained for 45 minutes. The temperature was lowered to -40°C at a rate of 0.8°C / min and maintained for 3 hours, and then heated to -15°C at a rate of 1.5°C / min and maintained for 3 hours, and then cooled to -28°C at a rate of 0.78°C / min and maintained for 4 hours to freeze the vaccine; after opening the cold well and dropping to below -50°C and vacuuming to 200mTorr, the temperature was raised to -5°C at a rate of 3°C / min, and maintained at this temperature for 12h; then heated to 10°C at a rate of 1.5°C / min and maintained for 3h; then heated to 10°C at a rate of 1.7°C / min and maintained for 4h; then heated to 28°C at a rate of 3°C / min and maintained for 4h. The vacuum degree of the entire drying process was controlled at 100±200mTorr. After the freeze-drying was completed, the plug was pressed out of the box, and the whole freeze-drying process was 30-33h. And compared with the process of Example 6, the specific results are shown in Table 9.

[0109] Table 9 Application loss of different freeze-drying processes in freeze-drying preparation of live pseudorabies vaccine

[0110]

[0111] It can be seen from the test data in Table 9 that the two different antigen processes for freeze-dried porcine pseudorabies vaccines have a titer loss of 0.97-0.99 after freeze-drying, and a comprehensive loss of 1.48-1.53 ​​titers; compared with the process of Example 6, this process cannot effectively solve the huge loss caused by the virus during the freeze-drying process. Therefore, it is recommended to use a slow freezing process when freeze-drying the vaccine product, and add an annealing step in combination with the characteristics of the virus to effectively protect the virus titer during freeze-drying and improve the quality of the vaccine product.

Claims

1. An ice crystal regulator, It is characterized in that The ice crystal regulator comprises the following components by mass percentage: 3%-8% fructose, 0.5%-3% magnesium chloride, 0.5%-5% inulin, 1%-5% sorbitol, 1%-5% hyaluronic acid, 0.1%-5% sodium alginate, 0.01%-1% anthocyanin, 0.5%-3% L-serine, and double-pure water to 100%.

2. The method for preparing the ice crystal regulating agent according to claim 1, It is characterized in that The following steps are involved: 1) Weigh fructose, magnesium chloride, inulin and sorbitol and dissolve them in water for injection. Dissolve them fully and heat to sterilize for 15-20 minutes before use. 2) Weigh hyaluronic acid, sodium alginate, anthocyanin, and L-serine and dissolve them in water for injection until fully dissolved. Filter and sterilize them for later use. 3) The solutions obtained in steps 1) and 2) are mixed under sterile conditions, and the pH of the solution is adjusted to 7.0-7.5 by using an alkaline reagent to obtain an ice crystal regulator.

3. Use of the ice crystal regulator according to claim 1 in the preparation of a freeze-dried vaccine of pseudorabies virus.

4. The use according to claim 3, It is characterized in that The volume ratio of the ice crystal regulator to the porcine pseudorabies virus is 1:15 to 1:

7.

5. The use according to claim 4, It is characterized in that The culture process of the porcine pseudorabies virus includes ST cell adherent culture or ST cell full suspension culture.

6. The use according to claim 4, It is characterized in that The application is: the ice crystal regulator of claim 1 is mixed with porcine pseudorabies virus at a volume ratio of 1:15 to 1:7 to obtain a semi-finished porcine pseudorabies virus live vaccine, the semi-finished porcine pseudorabies virus live vaccine is frozen and thawed, and then uniformly mixed with the ice crystal regulator at a volume ratio of 1:1 to 2:1 to obtain a vaccine solution, and vacuum freeze-drying is performed to obtain a freeze-dried live vaccine of porcine pseudorabies virus.

7. The use according to claim 6, It is characterized in that The freeze-drying procedure of the vacuum freeze drying comprises the following steps: placing the vaccine solution in a freeze-drying machine body and precooling it at 2-8°C for 15-45 minutes, and maintaining the temperature for 30-60 minutes; reducing the temperature to -35--40°C at a rate of 1°C / min-3°C / min and maintaining it for 1-2 hours, heating it to -25--28°C at a rate of 0.2°C / min-0.5°C / min and maintaining it for 2-4 hours, and then reducing the temperature to -35--40°C at a rate of 1°C / min-2.5°C / min and maintaining it for 2-4 hours, so that the vaccine is frozen; opening the cold well to reduce the temperature to below -50--60°C, and vacuuming the solution. After the pressure reaches 200mTorr, heat it to -15~-10℃ at a rate of 0.8℃ / ~min~1.5℃ / min, and maintain it at this temperature for 10~12h; heat it to 4℃ at a rate of 0.3℃ / min~0.8℃ / min, and maintain it for 5~8h; heat it to 20~25℃ at a rate of 0.5℃ / min~0.8℃ / min, and maintain it for 3~5h; heat it to 28~30℃ at a rate of 1℃ / min~2℃ / min, and maintain it for 2~3h; the vacuum degree of the whole drying process is controlled at 120~200mTorr. After freeze-drying, press the stopper out of the box.

8. A freeze-dried live vaccine of pseudorabies virus, It is characterized in that The freeze-dried live vaccine of pseudorabies virus comprises the ice crystal regulator as described in claim 1, and the preparation steps of the freeze-dried live vaccine of pseudorabies virus comprise: mixing the ice crystal regulator with pseudorabies virus at a volume ratio of 1:15 to 1:7 to obtain a semi-finished live vaccine of pseudorabies virus; freezing and thawing the semi-finished live vaccine of pseudorabies virus, uniformly mixing it with the ice crystal regulator at a volume ratio of 1:1 to 2:1 to obtain a vaccine solution; and vacuum freeze-drying is performed to obtain the freeze-dried live vaccine of pseudorabies virus.

9. The porcine pseudorabies virus freeze-dried live vaccine according to claim 8, It is characterized in that The volume ratio of the porcine pseudorabies virus to the ice crystal regulator is 1:1 to 2:1.